Multiple neurophysiologic biomarkers evaluated the pulmonary function of ALS.

Not Applicable

• Conditions: amyotrophic lateral sclerosis(ALS)

• Registration Number: JPRN-UMIN000042222
• Lead Sponsor: ara Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-23
• Study Completion: 2022-10-23
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who received unapproved drugs in Japan for ALS or underwent surgery within 12 months (48 weeks) before informed consent 2.Patients with dimentia(MMSE<10) 3.Patients with severe phychiatric disorder 4.Patients who are not able to answer questionnaires 5.Patients with suicidal ideation 6.Patients undergoing treatment for respiratory disease 7.Patients with severe heart failure 8.Patients with pregnancy 9.Patients judged to be inappropriate for this study by the investigator or coordinator

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The relationships between neurophysiological biomarkers (amplitude of diaphragmatic compound muscle action potential, diaphragm thickness measured by ultrasonography, thoracic excursion),%FVC of respiratory function test, PaCO2 of blood gas analysis.